![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Synvista Therapeutics, Inc |
---|---|
Information provided by: | Synvista Therapeutics, Inc |
ClinicalTrials.gov Identifier: | NCT00089713 |
This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phase. The combined total duration of patient participation is approximately 17-20 weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: alagebrium chloride (ALT-711) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Effect of ALT-711 in Combination With Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients |
Ages Eligible for Study: | 45 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New Jersey | |
Alteon Inc. | |
Parsippany, New Jersey, United States, 07054 |
Study Director: | Milan Kovacevic, MD, PhD | Synvista Therapeutics, Inc |
Study ID Numbers: | ALT-711-0320 |
Study First Received: | August 10, 2004 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00089713 |
Health Authority: | United States: Food and Drug Administration |
antihypertensive agents/therapeutic use hypertension/drug therapy blood pressure |
Vascular Diseases Hydrochlorothiazide Hypertension |
Cardiovascular Diseases |